Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Drug-associated porphyria: a pharmacovigilance study.
Orphanet J Rare Dis
August 2024
Department of Pharmacy, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Article Synopsis
- * Researchers analyzed ADRs related to porphyria from January 2004 to March 2022 and narrowed down 406 drugs, ultimately identifying 52 drugs associated with adverse effects using various statistical algorithms.
- * The findings provide essential insights into the safety of drugs for porphyria carriers, helping healthcare providers make informed decisions and avoid prescribing harmful medications.
Drug-Induced Pseudoporphyria: A Case Report.
Cureus
April 2024
Dermatology, Jawaharlal Nehru Medical College, Datta Meghe Institute of Higher Education and Research, Wardha, IND.
Article Synopsis
- - Pseudoporphyria is a rare skin condition that resembles porphyria cutanea tarda (PCT), and distinguishing between the two is crucial for accurate diagnosis.
- - It’s linked to chronic kidney failure, certain medications, and tanning bed use, and can cause skin issues like fragility, blisters, and scarring, especially in sun-exposed areas.
- - A case report highlights a 20-year-old male diagnosed with pseudoporphyria after ruling out true porphyria, who was treated with hydroxychloroquine sulfate and advised to take strict sun protection measures.
An unusual bullous eruption: olanzapine induced pseudoporphyria.
BMJ Case Rep
November 2019
Endocrinology, Royal Liverpool University Hospital, Liverpool, UK.
Article Synopsis
- - A 27-year-old man with schizophrenia developed blistering skin eruptions on his hands, forearms, and face over two days during summer, with no known exposure to chemicals or toxins.
- - Medical examinations showed large, tense blisters, and lab tests ruled out common causes, leading to a diagnosis of pseudoporphyria.
- - The patient's recent introduction of olanzapine, an atypical antipsychotic, was identified as the likely cause of his condition, emphasizing the need for thorough medication history inquiries in clinical settings.
Porphyria cutanea tarda: an intriguing genetic disease and marker.
Int J Dermatol
June 2017
Dermatology, Rutgers New Jersey Medical School, Newark, NJ, USA.
Porphyrias are a group of intriguing genetic diseases of the heme pathway, of which porphyria cutanea tarda (PCT) is the most common. Resulting from a defect in enzymes in the porphyria pathway, PCT has been linked to several conditions. Recent studies have demonstrated a change in thinking regarding the human immunodeficiency virus (HIV) and development of PCT.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!